UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
British journal of pharmacology, ISSN 0007-1188, 01/2006, Volume 147, Issue S1, pp. S252 - S257
PDE5 | asthma | inflammation | PDE4 | Phosphodiesterase | erectile dysfunction | Erectile dysfunction | Inflammation | Asthma | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Biological and medical sciences | Medical sciences | Chronic obstructive pulmonary disease, asthma | Pharmacology. Drug treatments | Pneumology | Phosphodiesterase Inhibitors - therapeutic use | Erectile Dysfunction - enzymology | Cyclic Nucleotide Phosphodiesterases, Type 4 | Cyclic Nucleotide Phosphodiesterases, Type 5 | Asthma - enzymology | Heart Failure - enzymology | Humans | Cyclic Nucleotide Phosphodiesterases, Type 3 | Phosphodiesterase Inhibitors - pharmacology | Male | Asthma - drug therapy | Heart Failure - drug therapy | Animals | Erectile Dysfunction - drug therapy | Inflammation - drug therapy | 3',5'-Cyclic-AMP Phosphodiesterases - antagonists & inhibitors | 3',5'-Cyclic-GMP Phosphodiesterases - antagonists & inhibitors | Inflammation - enzymology | Index Medicus | Applied Pharmacology
Journal Article
Frontiers in oncology, ISSN 2234-943X, 2019, Volume 9, pp. 681 - 681
Phosphodiesterase type 5 inhibitor | Non-homologous end joining DNA repair | Topoisomerase II inhibitor | Homologous recombination DNA repair | PDE5-independent | Life Sciences & Biomedicine | Oncology | Science & Technology | Usage | Care and treatment | Research | Phosphodiesterases | DNA repair | Prostate cancer | phosphodiesterase type 5 inhibitor | homologous recombination DNA repair | non-homologous end joining DNA repair | topoisomerase II inhibitor
Journal Article
The New England journal of medicine, ISSN 0028-4793, 11/2009, Volume 361, Issue 19, pp. 1864 - 1871
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Biological and medical sciences | General aspects | Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases | Medical sciences | Pneumology | Phosphodiesterase Inhibitors - therapeutic use | Sulfones - therapeutic use | Phosphodiesterase Inhibitors - adverse effects | Humans | Middle Aged | Phosphodiesterase 5 Inhibitors | Sulfones - adverse effects | Hypertension, Pulmonary - physiopathology | Anticoagulants - therapeutic use | Dyspnea - etiology | Piperazines - therapeutic use | Piperazines - adverse effects | Warfarin - therapeutic use | Sildenafil Citrate | Diuretics - therapeutic use | Female | Hypertension, Pulmonary - drug therapy | Purines - adverse effects | Purines - therapeutic use | Drug Therapy, Combination | Hypertension, Pulmonary - etiology | Practice Guidelines as Topic | Hypertension | Care and treatment | Usage | Causes of | Diagnosis | Phosphodiesterases | Health aspects | Proteins | Pulmonary arteries | Veins & arteries | Index Medicus | Abridged Index Medicus
Journal Article
Drug safety, ISSN 0114-5916, 2009, Volume 32, Issue 1, pp. 1 - 18
Pharmacology & Pharmacy | Public, Environmental & Occupational Health | Toxicology | Life Sciences & Biomedicine | Science & Technology | Phosphodiesterase Inhibitors - therapeutic use | Vision Disorders - physiopathology | Phosphodiesterase Inhibitors - adverse effects | Adverse Drug Reaction Reporting Systems | Erectile Dysfunction - drug therapy | Humans | Risk Factors | Phosphodiesterase 5 Inhibitors | Male | Clinical Trials as Topic | Vision Disorders - drug therapy | Index Medicus
Journal Article
Neurourology and urodynamics, ISSN 0733-2467, 08/2018, Volume 37, Issue 6, pp. 1865 - 1874
5‐alpha reductase inhibitors | alpha‐1adrenergic antagonists | benign prostatic obstruction | benign prostatic enlargement | phosphodiesterase type 5 inhibitors | phytotherapic compounds | alpha-1adrenergic antagonists | 5-alpha reductase inhibitors | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Medicine, Experimental | Sympathomimetic agents | Medical research | Analysis
Journal Article
Chest, ISSN 0012-3692, 2012, Volume 142, Issue 6, pp. 1383 - 1390
Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Cardiology. Vascular system | Biological and medical sciences | Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases | Medical sciences | Pneumology | Sulfones - therapeutic use | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Walking - physiology | Dose-Response Relationship, Drug | Sildenafil Citrate | Young Adult | Epoprostenol - therapeutic use | Epoprostenol - adverse effects | Adult | Female | Hypertension, Pulmonary - drug therapy | Phosphodiesterase 5 Inhibitors - therapeutic use | Purines - therapeutic use | Drug Therapy, Combination | Endothelin Receptor Antagonists | Double-Blind Method | Administration, Oral | Familial Primary Pulmonary Hypertension | Treatment Outcome | Piperazines - therapeutic use | Antihypertensive Agents - therapeutic use | Antihypertensive Agents - adverse effects | Epoprostenol - analogs & derivatives | Sulfonamides - therapeutic use | Exercise Tolerance - physiology | Adolescent | Aged | Epoprostenol - administration & dosage | Treprostinil | Dosage and administration | Research | Drug therapy | Patient outcomes | Pulmonary hypertension | Index Medicus | Abridged Index Medicus
Journal Article
Chest, ISSN 0012-3692, 2013, Volume 144, Issue 3, pp. 952 - 958
Respiratory System | Life Sciences & Biomedicine | Critical Care Medicine | General & Internal Medicine | Science & Technology | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension, Pulmonary - physiopathology | Male | Exercise Tolerance - drug effects | Dose-Response Relationship, Drug | Young Adult | Time Factors | Adult | Female | Blood Pressure - drug effects | Hypertension, Pulmonary - drug therapy | Drug Therapy, Combination | Endothelin Receptor Antagonists | Double-Blind Method | Administration, Oral | Phosphodiesterase 5 Inhibitors - administration & dosage | Familial Primary Pulmonary Hypertension | Treatment Outcome | Epoprostenol - analogs & derivatives | Adolescent | Aged | Vasodilator Agents - administration & dosage | Epoprostenol - administration & dosage | Complications and side effects | Care and treatment | Patient outcomes | Treprostinil | Clinical trials | Dosage and administration | Research | Drug therapy | Pulmonary hypertension | Index Medicus | Abridged Index Medicus
Journal Article
BJU international, ISSN 1464-4096, 08/2005, Volume 96, Issue 3, pp. 257 - 280
tadalafil | phosphodiesterase type 5 | safety | pharmacokinetics | cGMP | vardenafil | sildenafil | efficacy | erectile dysfunction | Tadalafil | Phosphodiesterase type 5 | Efficacy | Erectile dysfunction | Vardenafil | Safety | Sildenafil | Pharmacokinetics | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Nephrology. Urinary tract diseases | Biological and medical sciences | Genital system. Reproduction | Medical sciences | Pharmacology. Drug treatments | Phosphodiesterase Inhibitors - therapeutic use | Phosphodiesterase Inhibitors - adverse effects | Phosphodiesterase Inhibitors - pharmacokinetics | Cyclic Nucleotide Phosphodiesterases, Type 5 | Humans | Erectile Dysfunction - diagnosis | Male | Treatment Outcome | Erectile Dysfunction - etiology | Forecasting | Phosphoric Diester Hydrolases | Algorithms | Drug Interactions | Erectile Dysfunction - drug therapy | Penile Erection - drug effects | 3',5'-Cyclic-GMP Phosphodiesterases | Penile Erection - physiology | Prostatic Neoplasms - drug therapy | Index Medicus
Journal Article
9.
Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 06/2015, Volume 313, Issue 24, pp. 2449 - 2455
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Phosphodiesterase 5 Inhibitors - adverse effects | Carcinoma, Basal Cell - chemically induced | Humans | Middle Aged | Risk Factors | Logistic Models | Male | Skin Neoplasms - chemically induced | Case-Control Studies | Socioeconomic Factors | Drug Prescriptions - statistics & numerical data | Sweden | Animals | Erectile Dysfunction - drug therapy | Melanoma - chemically induced | Aged, 80 and over | Registries | Aged | Phosphodiesterase 5 Inhibitors - therapeutic use | Inhibitor drugs | Risk assessment | Clinical outcomes | Melanoma
Journal Article